The Trump administration imposed 100% tariffs on imported brand-name drugs, with exemptions for companies that agree to manufacture in the U.S. and lower drug prices, signaling a push towards domestic pharmaceutical production and affordability ahead of midterms. This move impacts developers and tech professionals by reshaping supply chains and potentially altering the competitive landscape for pharmaceutical technology solutions. Watch for further negotiations with smaller pharmaceutical companies aiming to avoid tariffs through similar deals.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)



